Brilliant Violet 570™ anti-mouse CD45.1

Catalog # / Size: 1153665 / 125 μl

Clone: A20

Isotype: Mouse IgG2a, κ

Immunogen: SJL mouse thymocytes and splenocytes

Reactivity: Mouse

Preparation: The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 570™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 570™ and


unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and BSA

(origin USA).

Concentration: Lot-specific



SJL mouse splenocytes were stained with CD45.1 (clone A20) Brilliant Violet 570™ (filled histogram) or mouse IgG2a, κ Brilliant Violet 570™ isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 570™ excites at 405 nm and emits at 570 nm. The bandpass filter 585/42 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 570™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes:

The A20 antibody does not react with leukocytes or mouse cells expressing the CD45.2 alloantigen. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation3, *in vitro* blocking of B cell responses^{1,2}, immunohistochemical staining of frozen sections: OCT embedded⁷ and acetone-fixed⁴⁻⁶ (direct immunofluorescence detection with fluorochrome conjugated A20 was used in (5) and (6)), and immunofluorescence microscopy⁹.

Application 1. Yakura H, *et al.* 1983. *J. Exp. Med.* 157:1077. (Block) **References:** 2. Yakura H, *et al.* 1986. *J. Immunol.* 136:2729. (Block)

- 3. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
- 4. Suzuki K, et al. 2000. Immunity 13:691. (IHC)
- 5. Werner N, et al. 2002. Arterioscler. Thromb. Vasc. Biol. 22:1567. (IHC)
- 6. Lessner SM, et al. 2002. Am. J. Pathol. 160:2145. (FC, IHC)
- 7. Chen CC, et al. 2005. P. Natl. Acad. Sci. USA 102:11408 (IHC)
- 8. Pascal V, et al. 2007. J. Immunol. 179:1751. (FC)
- 9. Mende I, et al. 2006. Blood 107:1383. (IF, IHC, FC)
- 10. Phan TG, et al. 2007. Nature Immunol. 8:992. (FC)
- 11. Wither DR, et al. 2009. J. Immunol. 183:5079. PubMed
- 12. Pascal V, et al.2007. J. Immunol. 179:1751. PubMed
- 13. Lee SW, et al. 2009. J. Immunol. 182:6753. PubMed
- 14. Takada K, et al. 2009. J. Exp Med. 206:2253. PubMed
- 15. Beamer CA, et al. 2007. Am. J. Respir. Cell. Mol. Biol. 37:729. (FC) PubMed
- 16. Li LX, et al. 2010. J. Immunol. 184:1728. PubMed
- 17. Hosoi A, et al. 2008. Cancer Res. 68:3941. (FC) PubMed
- 18. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
- 19. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed

Description:

CD45.1 is an alloantigen of CD45, expressed by Ly5.1 bearing mouse strains (e.g., RIII, SJL/J, STS/A, DA). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in mice that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell types. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Antigen References:

- 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
- 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
- 3. Kishihara K, et al. 1993. Cell 74:143.
- 4. Pulido R, <